5e5 of anti-MSLN CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human Mesothelin (296-580), His Tag Star staining (Cat. No. MSN-HP2H8) and negative control protein respectively(Fig. C and B), and non- transfected 293 cells were used as a control (Fig. A). PE signal was used to evaluate the binding activity (QC tested).
Anti-human MSLN mAb (chimeric mouse-human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface, can bind RFP Fusion Human Mesothelin (296-580), His Tag (Cat. No. MSN-HR2P4) with an affinity constant of 0.304 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Anti-human MSLN MAb (chimeric mouse-human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface, can bind GFP Fusion Human Mesothelin (296-580), His Tag (Cat. No. MSN-HG2P4) with an affinity constant of 0.542 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| RNA-Meso-CIR-T | RNA-Meso-CIR-T | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Mesothelioma | Details |
| Anti-mesothelin CAR-T (Pregene) | Clinical | Pregene (Shenzhen) Biotechnology Co Ltd | Hydrothorax | Details | |
| Autologous Mesothelin-specific TCR-T Cell Therapy (Lonza Walkersville) | Phase 1 Clinical | Pancreatic Neoplasms | Details | ||
| Anetumab ravtansine | BAY-94-9343; BAY-94-9343-SPDB-DM4; Anti-mesothelin antibody-drug conjugate BAY 94-9343 | Phase 1 Clinical | Bayer Ag, Morphosys | Ovarian Neoplasms; Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung | Details |
| Anti-MESO CAR-T cell(Ruijin Hospital) | Phase 1 Clinical | Ruijin Hospital, Shanghai Jiaotong University School Of Medicine | Neoplasms | Details | |
| Gavocabtagene autoleucel | TC-210 | Phase 2 Clinical | Tcr2 Therapeutics | Ovarian Neoplasms; Mesothelioma; Cholangiocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| iCasp9M28z | iCasp9M28z | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Mesothelioma; Breast Neoplasms; Lung Neoplasms; Neoplasm Metastasis | Details |
| LMB-100 | LMB-100; RG-7787; RO-6927005 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Neoplasms; Mesothelioma | Details |
| RC-88 | RC-88 | Phase 1 Clinical | RemeGen Co Ltd | Solid tumours | Details |
| MCY-M11 | MCY-M11 | Phase 1 Clinical | Maxcyte | Ovarian Neoplasms; Mesothelioma; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Adenocarcinoma | Details |
| Amatuximab | MORAb-009; MORAB-009-006 | Phase 2 Clinical | National Cancer Institute | Ovarian Neoplasms; Neoplasms; Pancreatic Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung | Details |
| KD-021 (Nanjing KAEDI Biotech) | KD-021 | Phase 1 Clinical | Nanjing Kaedi Biotechnology Co Ltd | Neoplasms | Details |
| anti-mesothelin thorium-227 labeled antibody chelator conjugate | BAY-2287411 | Phase 1 Clinical | Bayer Ag | Ovarian Neoplasms; Mesothelioma; Carcinoma, Pancreatic Ductal; Adenocarcinoma | Details |
| LCAR-M23 | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Carcinoma, Ovarian Epithelial | Details | |
| anti-MESO CAR-T cells (Zhejiang University) | Phase 2 Clinical | Zhejiang University | Ovarian Neoplasms | Details | |
| ATA-2271 | ATA-2271 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Atara Biotherapeutics, Bayer Ag | Mesothelioma | Details |
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
| Anti-mesothelin CAR-NK | Phase 1 Clinical | Guojianchengnuo Biotechnology (Beijing) Co Ltd | Carcinoma, Ovarian Epithelial | Details |
This web search service is supported by Google Inc.
A-Z
